Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 May 2017

Wang Hsin-Yi, Ho Chao-Chi, Shih Jin-Yuan

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ALK gene

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 28434515
DOI: 10.1016/j.jtho.2017.01.009

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.PMID 28434515Read ↗

Targeting drug-resistant mutations in ALK.Semantic proximity Read ↗

Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?Semantic proximity Read ↗

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesSemantic proximity Read ↗

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.Semantic proximity Read ↗

[Molecular targeted drugs against ALK fusions].Semantic proximity Read ↗

Mechanisms of acquired resistance to tyrosine kinase inhibitorsSemantic proximity Read ↗

Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.Semantic proximity Read ↗

Targeting ALK: Precision Medicine Takes on Drug Resistance.Semantic proximity Read ↗

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.Semantic proximity Read ↗

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Semantic proximity Read ↗

EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the LiteratureSemantic proximity Read ↗

New mutation L324M in the ABL1 kinase domain: does it confer high resistance to second-generation inhibitors?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.